Apr 21 2010
The Montgomery Breast Center of Montgomery, Ala., is the first center in the country to install and use the GammaLoc® lesion-localization system. This system is the only FDA-cleared device that enables gamma-guided, minimally invasive needle biopsy of suspicious lesions identified with Breast-Specific Gamma Imaging (BSGI). BSGI is performed by the Dilon 6800®, a gamma camera that is optimized to reveal lesions independent of tissue density and discover early stage cancers that are oftentimes not identified with other imaging methods, such as mammography, ultrasound and magnetic resonance imaging (MRI).
GammaLoc® helps the physician calculate the specific depth and location of the suspect lesion. A computer user interface with detailed step-by-step instructions guides the physician through the biopsy procedure. The GammaLoc® system utilizes a CorreLocator™ paddle and a StereoView™ imaging collimator system – a technique similar to that used in stereotactic X-ray localization.
Dr. Cynthia Lorino, Director of Breast Imaging at Montgomery Breast Center, has already performed successful biopsies with the GammaLoc® system. "This device allows for precise and efficient biopsies," she said. "BSGI often discovers cancerous lesions that are not seen on mammograms or ultrasound. Now we have a way to quickly sample this suspicious tissue and give accurate results for patient peace of mind."
The entire GammaLoc® system is small and portable, allowing physicians to perform molecular imaging-guided biopsy procedures anywhere on site. The compact design allows for 180-degree access during breast biopsies with optimal patient comfort.
"GammaLoc® is a significant tool for us to more effectively locate breast cancer and determine the best course of treatment," said Dr. Lorino.
SOURCE Dilon Diagnostics, Inc.
New 3D body scan method beats traditional imaging for tracking body fat